The MEG3 lncRNA promotes trophoblastic cell growth and invasiveness in preeclampsia by acting as a sponge for miR-21, which regulates BMPR2 levels

Autor: Huyi Liu, Xiangdao Cai, Jia Liu, Fengxiang Zhang, Andong He, Ruiman Li

Publikováno v: European Journal of Histochemistry, Vol 65, Iss 4 (2021)

Preeclampsia (PE) is one of the leading causes of maternal morbidity and mortality in pregnant women. This study aimed to investigate the potential impact and regulatory mechanisms of bone morphogenetic protein receptor 2 (BMPR2) on the progression o

Externí odkaz: https://doaj.org/article/dd5d2ec110d34e798b04a6628cb94ca1

Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers

Autor: Gu, Mingxia ^{1, 2, 3, 7}, Shao, Ning-Yi ^{2, 4, 7}, Sa, Silin ^{1, 2, 3}, Li, Dan ^{1, 2, 3}, Termglinchan, Vittavat ^{2, 4}, Ameen, Mohamed ^{2, 4}, Karakikes, Ioannis ^{2, 4}, Sosa, Gustavo ^{1, 2, 3}, Grubert, Fabian ⁵, Lee, Jaecheol ^{2, 4}, Cao, Aiqin ^{1, 2, 3}, Taylor, Shalina ^{1, 2, 3}, Ma, Yu ^{2, 4}, Zhao, Zhixin ⁵, Chappell, James ⁵, Hamid, Rizwan ⁶, Austin, Eric D. ⁶, Gold, Joseph D. ², Wu, Joseph C. ^{2, 4, ∗}, Snyder, Michael P. ^{2, 5, ∗∗}, Rabinovitch, Marlene ^{1, 2, 3, 8, ∗∗∗}

Publikováno v: In Cell Stem Cell 6 April 2017 20(4):490-504

Genetic counselling and testing in pulmonary arterial hypertension -A consensus statement on behalf of the International Consortium for Genetic Studies in PAH

Autor: Eichstaedt, Christina A., Belge, Catharina, Chung, Wendy K., Gräf, Stefan, Grünig, Ekkehard, Montani, David, Quarck, Rozenn, Tenorio-Castano, Jair A., Soubrier, Florent, Trembath, Richard C., Morrell, Nicholas W., Aldred, Micheala A., Archer, Stephen L., Austin, Eric D., Badagliacca, Roberto, Balanchandar, Srimmitha, Barberà, Joan Albert, Benza, Raymond L., Berger, Rolf M.F., Bogaard, Harm Jan, Bonnet, Sébastien, Boomars, Karin A., Boucherat, Olivier, Chakinala, Murali M., Condliffe, Robin, Damico, Rachel Lynn, Delcroix, Marion, Desai, Ankit A., Doboszynska, Anna, Dooijes, Dennis, Elliott, C. Greg, Eyries, Melanie, Subías, Maria Pilar Escribano, Gall, Henning, García-Aranda, Beatriz, Ghio, Stefano, Ghofrani, Hossein Ardeschir, Hamid, Rizwan, Hassoun, Paul M., Hemnes, Anna R., Hinderhofer, Katrin, Houweling, Arjan C., Howard, Luke S., Humbert, Marc, Kiely, David G., Kovacs, Gabor, Langleben, David, Lapunzina, Pablo, Lawrie, Allan, Loyd, Jim E.

Publikováno v: European Respiratory Journal, 61(2):2201471. European Respiratory Society
PAH-ICON 2023, ' Genetic counselling and testing in pulmonary arterial hypertension : a consensus statement on behalf of the International Consortium for Genetic Studies in PAH ', European Respiratory Journal, vol. 61, no. 2, 2201471 . https://doi.org/10.1183/13993003.01471-2022

Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely) pathogenic germline genomic variants. In addition to the most prevalent disease gene, BMPR2 (bone morphogenetic protein receptor 2), several genes, some belonging

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892947a5bbd2b3a7cb8d25fbe3df3918
https://pubmed.ncbi.nlm.nih.gov/36302552

Role of apoptosis in pulmonary hypertension: From experimental models to clinical trials

Autor: Jurasz, Paul ^a, Courtman, David ^{a, b}, Babaie, Saeid ^f, Stewart, Duncan J. ^{a, b, c, d, e, ⁎}

Publikováno v: In Pharmacology and Therapeutics 2010 126(1):1-8

Severe pulmonary arterial hypertension is characterized by increased neutrophil elastase and relative elafin deficiency

Autor: Richard D. Bland, Emilia M. Swietlik, Andrew J. Sweatt, Roham T. Zamanian, Mark R. Nicolls, Christopher J. Rhodes, Kazuya Miyagawa, Edda Spiekerkoetter, Shalina Taylor, Patricia A. del Rosario, Andrew Hsi, Stefan Gräf, Nicholas W. Morrell, Marlene Rabinovitch, Michal Bental-Roof, Francois Haddad, Martin R. Wilkins

Publikováno v: Chest

Background Preclinical evidence implicates neutrophil elastase (NE) in pulmonary arterial hypertension (PAH) pathogenesis, and the NE inhibitor elafin is under early therapeutic investigation. Research Question Are circulating NE and elafin levels ab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2effa4d59e57aa6956f99914ffc92b2
http://hdl.handle.net/10044/1/90261